Breaking News

GVK Bio Passes FDA Audit

No 483s at Clinical Pharmacology Unit

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

GVK Biosciences’ Clinical Pharmacology Unit in Ahmedabad successfully cleared an FDA audit with no 483s or observations. The agency visited and audited a First-to-File study for one of GVK Bio’s customers. The GVK Bio Ahmedabad facility, commissioned in 2010, has three clinics with 110 beds. The facility has been inspected and approved by Drugs Controller General of India (DCGI), ANVISA-Brazil and Ministry of Health (MoH)-Turkey. The Ahmedabad facility carries out Bioavailability and Bioe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters